Protocol Ledger

NCT05613023 · Phase III · RECRUITING

A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT

Interventional Phase III clinical trial protocol NCT05613023 sponsored by Institute of Cancer Research, United Kingdom in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-09-09 Enrollment: 1,128 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT05613023
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)1,128 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05613023
Protocol FieldVerified Registry Value
NCT IdentifierNCT05613023
Consolidated Lead SponsorInstitute of Cancer Research, United Kingdom
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase III
Overall Recruitment StatusRECRUITING
Registered Enrollment1,128 participants (ESTIMATED)
Registered Start Date2022-09-09
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT05613023
Hospital Research SiteLocationSite Profile
Royal Free HospitalLondon, United KingdomOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI